Bellerophon Reports 2015 First Quarter Financial and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Bellerophon Reports 2015 First Quarter Financial and Operational Results

HAMPTON, N.J., May 15, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH ), a clinical-stage biotherapeutics company, today reported financial results for the first quarter ended March 31, 2015.

"This has been a productive quarter for Bellerophon," said Jonathan Peacock, Chairman and Chief Executive Officer of Bellerophon Therapeutics. "We completed our initial public offering in February 2015, raising $51.9 million of net proceeds, after underwriting discounts and offering expenses, to fund our ongoing clinical trials and we are on track to deliver on our plans for both of our key programs. In our INOpulse ® program, we expect to start enrolling the first patients in our Phase 3 trial for pulmonary arterial hypertension (PAH) in the second half of this year. We also expect to report top line results in mid-2015 from our CE Mark registration trial for our bioabsorbable cardiac matrix (BCM) program for the prevention of ventricular remodeling following a heart attack."

First Quarter 2015 Financial Results

For the first quarter of 2015, Bellerophon reported a net loss of $12.9 million, a reduction from a net loss of $14.5 million for the first quarter 2014. The decrease in net loss was primarily due to a reduction in research and development expenses as well as lower net payments to Ikaria, Inc., net of income received in connection with a new services agreement signed in the first quarter of 2015, partially offset by the incremental costs of setting up and operating as a standalone public company and by one-time items.

Research and development expenses for the first quarter of 2015 decreased to $9.5 million from $12.0 million in the first quarter of 2014. The decrease in research and development expenses was primarily due to reduced clinical activity related to PH-COPD in the first quarter of 2015 compared to the same period in 2014, as the company completed the Phase 2 trial of INOpulse for PH-COPD in mid-2014. The decrease was partially offset by increases in spending for INOpulse Mark2 development and other investments in preparation for the anticipated Phase 3 trial planned for the second half of 2015.

General and administrative expenses for the first quarter of 2015 were $4.6 million compared with $2.5 million for the first quarter of 2014. The increase in general and administrative expense primarily resulted from additional costs of operating as a standalone public company, including expenses related to transition services from our former parent, Ikaria, and from certain one-time expenses, including costs associated with the resolution of a dispute with BioLineRx Ltd. relating to the company's license to BCM.

Financial Highlights

As of March 31, 2015, the company had cash, cash equivalents and restricted cash of $71.4 million. In the quarter, the company completed its IPO, which raised $60.0 million of gross proceeds and $51.9 million of net proceeds, after underwriting discounts and offering expenses, from the sale of 5,000,000 shares of its common stock. The company estimates that its cash, cash equivalents and restricted cash as of March 31, 2015, will enable it to fund its planned operating expenses and capital expenditure requirements at least into mid-2016.

About Bellerophon

Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. The Company has two programs in advanced clinical development. The first program, INOpulse, is based on the Company's proprietary pulsatile nitric oxide delivery device. The Company is currently developing two product candidates under its INOpulse program: one for the treatment of pulmonary arterial hypertension (PAH), for which the Company intends to commence Phase 3 clinical trials in the second half of 2015, and the other for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), which is in Phase 2 development. The Company's second program is bioabsorbable cardiac matrix (BCM), an injectable device for the prevention of cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction (AMI), commonly known as a heart attack. BCM is currently in a placebo-controlled clinical trial, expected to report top-line results in mid-2015, designed to support CE mark registration in the European Union and, assuming positive results, to provide the basis for an additional registration trial in the United States. Bellerophon has an exclusive worldwide license to BCM from BioLineRx Ltd. For more information, visit www.bellerophon.com .

Forward-looking Statements

Any statements in this press release about our future expectations, plans and prospects, including statements about clinical development of our product candidates and expectations regarding the sufficiency of our cash balance to fund clinical trials, operating expenses and capital expenditures, and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals, availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" section of our most recent filings with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update any forward-looking statements included in this press release.

Bellerophon Therapeutics, LLC
     
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share amounts) (Unaudited)
     
  Three Months Ended  March 31,
  2015 2014
     
Operating expenses:    
Research and development  $ 9,520  $ 12,040
General and administrative  4,573  2,470
Total operating expenses  14,093  14,510
Other operating income  1,166  --
Loss from operations  (12,927)  (14,510)
Interest Income  19  -- 
Pre-tax loss  (12,908)  (14,510)
Income tax benefit (expense)  --   --
Net loss and comprehensive loss  $ (12,908)  $ (14,510)
     
Weighted average shares/units outstanding:    
Basic and diluted  10,152,487  7,899,251
     
Net loss per share/unit:    
Basic and diluted  $ (1.27)  $ (1.84)
 
 
Bellerophon Therapeutics
     
Condensed Consolidated Balance Sheet
(In thousands) (Unaudited)
     
  March 31, 2015  December 31, 2014 
     
Assets    
     
Current assets:    
Cash and cash equivalents  $ 62,935  $ 16,815
Restricted cash  8,497  9,264
Receivables - Due from Ikaria, Inc.   167  -- 
Prepaid expenses and other current assets  1,974  1,602
Total current assets  73,573  27,681
     
Restricted cash, non-current  --  1,548
Deferred transaction costs  --  2,466
Property and equipment, net  1,604  1,696
Total assets  $ 75,177  $ 33,391
     
     
Liabilities and Stockholders' / Members' Equity    
     
Current liabilities:    
Accounts payable  $ 659  $ 376
Accrued research and development  7,235  6,666
Accrued expenses  3,825  2,751
Due to Ikaria, Inc.  1,069  661
Total current liabilities  12,788  10,454
Total liabilities  12,788  10,454
     
Total stockholders' / members' equity  62,389  22,937
     
Total liabilities and stockholders' / members' equity  $ 75,177  $ 33,391

At Bellerophon: Manesh Naidu, Chief Business Officer (908) 574-4770 At Rx Communications Group: Paula Schwartz (Investors) (917) 322-2216 Eric Goldman (Media) (917) 322-2563

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rox Taps Dynamics 365 Without Forcing a CRM Reset Yet

Updated Category News Views 89

Enterprise software buyers hate renovations when a useful extension will do. Rox’s new integration with Microsoft Dynamics 365 Sales, announced November 19, 2026, is built around that unglamorous but very real fact. The company is not asking a Global 2000 sales organization to rip out its customer system, retrain everybody, and pray an AI layer somehow pays for the...

Continue Reading
Minno Bets on Listener Kids to Build Premium Growth

Updated Category News Views 97

Children’s media rarely gets a clean strategic move, but this one comes pretty close. Minno has signed a worldwide, multi-year agreement making it the exclusive faith-based streaming home for Listener Kids’ video library, while commissioning 66 new episodes for its own service. For a company trying to build a serious Christian family-media business, that is more than...

Continue Reading
NYSE Message Record Puts Market Plumbing Into Focus

Updated Category News Views 120

A trillion messages is not a cute little exchange statistic; it is the sort of number that tells you whether the market’s pipes can keep working when everybody starts shouting at once. NYSE says it handled a record 1.166 trillion messages in one day on November 5, roughly 4% above the prior high set amid April 2025 volatility. Better yet, according to the exchange,...

Continue Reading
UnitedHealth’s CMS Audit Shock Puts Disclosures Under Lens

Updated Category News Views 62

Medicare Advantage's audit bill just landed with a nasty thud. UnitedHealth Group shares fell more than 10% on November 18 after the Centers for Medicare & Medicaid Services proposed new anti-fraud, audit, and repayment rules for the program. For holders of NYSE:UNH, this was not some sleepy policy memo buried in a federal filing cabinet. It was a hard reminder that...

Continue Reading
First Horizon Opens Its Charlotte Office in South End

Updated Category News Views 20

A Building Is Not a Balance Sheet Charlotte got a fresh First Horizon sign at 110 East Boulevard on Nov. 19, 2026, and that is a sensible move, not a magic trick. The bank has officially opened a corporate office in the city’s South End neighborhood, positioning the team to develop client relationships across the Charlotte area and broaden its regional footprint. That...

Continue Reading
SwitchBot's Black Friday Sale Tests Smart Home Demand

Updated Category News Views 112

Holiday gadget season is where clever home-tech pitches either earn their keep or gather dust in a warehouse. SwitchBot is coming into Black Friday 2026 with discounts of up to 50% on select products, running from November 19 through Cyber Monday on November 30. The lineup is broad enough to matter: decorative color E Ink frames, automated curtains and blinds, an indoor...

Continue Reading
Honda Prelude’s Hybrid Return Tests a Narrow Niche

Updated Category News Views 22

A low-slung coupe showing up in Newfoundland is not exactly a volume-sales thunderclap, and that is precisely why the 2027 Honda Prelude deserves a closer look. Steele Honda in St. John’s is presenting the hybrid two-door as a fresh choice for buyers who want something livelier than the usual practical commuter. For Honda, and for investors watching Honda Motor Co....

Continue Reading
Thanksgiving Kitchen Safety Is No Place for Autopilot

Updated Category News Views 87

Steam, chatter, and one forgotten burner can turn a holiday meal ugly in a hurry. The Consumer Product Safety Commission’s Nov. 19, 2026 reminder lands on a point that should not need repeating, yet plainly does: Thanksgiving kitchens demand attention, not casual optimism. This is not about ruining anybody’s celebration with a lecture. It is about recognizing that a...

Continue Reading
RBC Signals Gets $10 Million to Push Space Infrastructure

Updated Category News Views 102

Ground stations are the unglamorous plumbing of the space economy, and somebody finally put fresh capital behind the wrench. RBC Signals says it has received a $10 million strategic growth investment led by Washington Harbour Partners, aimed at enlarging its government-services operation and pushing several newer space-connectivity tools toward commercial use. This is a...

Continue Reading
Borr’s Q3 Presentation Puts Jack-Up Investors on Watch

Updated Category News Views 93

Jack-up drilling is a rough business to judge from a calendar invite, but Borr Drilling has put a useful marker in the sand. The company is scheduled to present financial results for the three and nine months ended September 30, 2026, at 09:00 New York time, or 15:00 CET, on Thursday, November 19. For holders of BORR, this is less about ceremonial webcast chatter and more...

Continue Reading

Top 5 Most Recently Viewed Articles

Global Surge in Panic Attack Treatment Market Anticipated

Updated Category News Views 140

Overview of the Panic Attack Treatment Market The panic attack treatment market is on a remarkable trajectory, anticipated to grow significantly in the coming years. The global market value is expected to soar from USD 2.92 billion to USD 8.66 billion, averaging a compound annual growth rate (CAGR) of 16.8%. This growth reflects a broader understanding and acceptance of...

Continue Reading
YipitData Enhances Global Insights in Europe and China

Updated Category News Views 196

YipitData Expands Global Insights YipitData, a prominent provider of alternative data, has announced its significant expansion into the European and Chinese markets. This exciting development follows the company's dedication to serving over 500 investors, facilitating deep insights into brand performance that influence market strategies. With the launch of new products...

Continue Reading
Silver Viper Minerals Makes Strategic Move to Acquire Coneto Project

Updated Category News Views 224

Silver Viper Minerals Announces Acquisition of Coneto Project Silver Viper Minerals Corp. has recently reached a binding agreement to acquire the Coneto Silver-Gold Project. This acquisition marks a significant milestone in the company's growth strategy, enabling it to expand its interests in the precious metals landscape of Mexico. Details of the Acquisition The...

Continue Reading
Vendasta Celebrated for Its Innovative Corporate Culture

Updated Category News Views 130

Vendasta Honored as a Top Corporate Culture in Canada Vendasta, a pioneering force in artificial intelligence solutions, has recently received commendation as one of Canada’s Most Admired Corporate Cultures. This recognition highlights the extraordinary environments that companies cultivate, significantly impacting their overall success. The award, given by Waterstone...

Continue Reading
Nordic Capital Exits ArisGlobal; Dassault Systèmes Wins

Updated Category News Views 22

Strategic Sale: Nordic Capital Exits with ArisGlobal Sometimes in this market, ya gotta hand the reins over after running a long game, and that's what Nordic Capital's doing with ArisGlobal. After investing heavily to turn ArisGlobal into an AI-enabled juggernaut in the life sciences sector, Nordic's calling it a day and selling the whole package to Dassault Systèmes. I...

Continue Reading